197 related articles for article (PubMed ID: 19020111)
21. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
22. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
23. Aflunov(®): a prepandemic influenza vaccine.
Gasparini R; Amicizia D; Lai PL; Panatto D
Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
[TBL] [Abstract][Full Text] [Related]
24. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
Moris P; van der Most R; Leroux-Roels I; Clement F; Dramé M; Hanon E; Leroux-Roels GG; Van Mechelen M
J Clin Immunol; 2011 Jun; 31(3):443-54. PubMed ID: 21174144
[TBL] [Abstract][Full Text] [Related]
25. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.
Banzhoff A; Pellegrini M; Del Giudice G; Fragapane E; Groth N; Podda A
Influenza Other Respir Viruses; 2008 Nov; 2(6):243-9. PubMed ID: 19453401
[TBL] [Abstract][Full Text] [Related]
26. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
[TBL] [Abstract][Full Text] [Related]
27. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
28. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.
Langley JM; Risi G; Caldwell M; Gilderman L; Berwald B; Fogarty C; Poling T; Riff D; Baron M; Frenette L; Sheldon E; Collins H; Shepard M; Dionne M; Brune D; Ferguson L; Vaughn D; Li P; Fries L
J Infect Dis; 2011 Jun; 203(12):1729-38. PubMed ID: 21606531
[TBL] [Abstract][Full Text] [Related]
29. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
30. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.
Höschler K; Gopal R; Andrews N; Saville M; Pepin S; Wood J; Zambon MC
Influenza Other Respir Viruses; 2007; 1(5-6):199-206. PubMed ID: 19453427
[TBL] [Abstract][Full Text] [Related]
31. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
van Doorn E; Liu H; Ben-Yedidia T; Hassin S; Visontai I; Norley S; Frijlink HW; Hak E
Medicine (Baltimore); 2017 Mar; 96(11):e6339. PubMed ID: 28296763
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines.
Ohshima N; Iba Y; Kubota-Koketsu R; Yamasaki A; Majima K; Kurosawa G; Hirano D; Yoshida S; Sugiura M; Asano Y; Okuno Y; Kurosawa Y
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050014
[TBL] [Abstract][Full Text] [Related]
36. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
37. Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks.
Kim JK; Seiler P; Forrest HL; Khalenkov AM; Franks J; Kumar M; Karesh WB; Gilbert M; Sodnomdarjaa R; Douangngeun B; Govorkova EA; Webster RG
J Virol; 2008 Nov; 82(22):11374-82. PubMed ID: 18786988
[TBL] [Abstract][Full Text] [Related]
38. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
39. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
40. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
